Phreesia (NYSE:PHR) Receives “Hold” Rating from Truist Financial

Truist Financial reissued their hold rating on shares of Phreesia (NYSE:PHR) in a research report released on Tuesday morning, MarketBeat.com reports. Truist Financial currently has a $11.00 target price on the stock, down from their previous target price of $24.00.

PHR has been the topic of several other reports. Royal Bank Of Canada assumed coverage on Phreesia in a report on Friday, January 9th. They set a “moderate buy” rating and a $26.00 price objective on the stock. Zacks Research lowered shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Phreesia in a report on Wednesday, January 28th. Wells Fargo & Company lowered their price target on shares of Phreesia from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, March 26th. Finally, DA Davidson reduced their price objective on Phreesia from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Thirteen investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $22.00.

Phreesia Stock Performance

PHR opened at $8.33 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The stock has a market capitalization of $502.28 million, a price-to-earnings ratio of 277.70 and a beta of 0.67. The company has a fifty day moving average of $12.36 and a 200 day moving average of $17.57. Phreesia has a fifty-two week low of $7.77 and a fifty-two week high of $32.76.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.05). The company had revenue of $127.07 million during the quarter, compared to analysts’ expectations of $126.75 million. Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.11) EPS. As a group, sell-side analysts forecast that Phreesia will post -1.1 earnings per share for the current fiscal year.

Insider Activity

In other news, General Counsel Allison C. Hoffman sold 6,585 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $112,010.85. Following the sale, the general counsel owned 174,762 shares of the company’s stock, valued at approximately $2,972,701.62. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Balaji Gandhi sold 8,009 shares of the firm’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $136,233.09. Following the completion of the sale, the chief financial officer owned 156,231 shares of the company’s stock, valued at $2,657,489.31. This trade represents a 4.88% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 70,358 shares of company stock worth $1,123,569. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Phreesia

Institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. boosted its position in shares of Phreesia by 2.7% during the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock valued at $400,000 after buying an additional 375 shares during the period. Diversified Trust Co raised its holdings in shares of Phreesia by 1.7% in the third quarter. Diversified Trust Co now owns 45,822 shares of the company’s stock worth $1,078,000 after buying an additional 780 shares during the period. Alliancebernstein L.P. raised its holdings in shares of Phreesia by 1.3% in the third quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock worth $1,475,000 after buying an additional 812 shares during the period. Van ECK Associates Corp lifted its stake in shares of Phreesia by 78.7% during the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after acquiring an additional 1,102 shares during the last quarter. Finally, Arizona State Retirement System lifted its stake in shares of Phreesia by 8.1% during the 3rd quarter. Arizona State Retirement System now owns 17,608 shares of the company’s stock worth $414,000 after acquiring an additional 1,313 shares during the last quarter. Institutional investors own 92.10% of the company’s stock.

Key Headlines Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Quarter results showed revenue growth and improved cash generation, with management flagging free cash flow and adjusted EBITDA milestones reached — evidence the business is profitable and generating cash. Business Wire: Phreesia Announces Fourth-Quarter Fiscal 2026 Results
• Neutral Sentiment: Several firms reaffirmed neutral/hold ratings but cut price targets, reflecting mixed conviction — e.g., JPMorgan (neutral, PT $16 from $24), Robert W. Baird (neutral, PT $10 from $25), Citigroup (neutral, PT $10 from $25), and Truist (hold, PT $11 from $24). These actions compress near-term upside expectations even where conviction remains. Benzinga: Why Is Phreesia Stock Sinking Tuesday?
• Negative Sentiment: Management cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the selloff and for multiple analyst downgrades/price-target reductions. Benzinga: Guidance cut explained
• Negative Sentiment: Major brokers sharply trimmed targets and/or ratings (examples: Stephens cut PT to $20 but kept overweight; BMO to $14/outperform; Canaccord to $22/buy; Needham to $14/buy), increasing near-term downside pressure despite some upbeat long-term views. Benzinga: Analyst price target updates
• Negative Sentiment: Market reaction: shares plunged and hit fresh lows on the guidance cut with unusually high volume, signaling broad investor de-risking and driving further volatility. MarketWatch: Shares touch all-time lows

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.